High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries

BACKGROUND: We aimed to elucidate which vaccines were accepted by European countries as valid proof of vaccination against COVID-19 for international travelers. METHOD: On 27-September-2021 a cross-sectional study was conducted on VisaGuide.World, that reports on valid vaccines for international tra...

Full description

Bibliographic Details
Published in:Travel Medicine and Infectious Disease
Main Authors: Dal-Ré, Rafael, Banzi, Rita, Becker, Sören L., Launay, Odile, Pavli, Androula
Format: Text
Language:English
Published: Elsevier Ltd. 2022
Subjects:
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/
https://doi.org/10.1016/j.tmaid.2022.102321
id ftpubmed:oai:pubmedcentral.nih.gov:8977214
record_format openpolar
spelling ftpubmed:oai:pubmedcentral.nih.gov:8977214 2023-05-15T16:50:58+02:00 High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries Dal-Ré, Rafael Banzi, Rita Becker, Sören L. Launay, Odile Pavli, Androula 2022 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ https://doi.org/10.1016/j.tmaid.2022.102321 en eng Elsevier Ltd. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ http://dx.doi.org/10.1016/j.tmaid.2022.102321 © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Travel Med Infect Dis Article Text 2022 ftpubmed https://doi.org/10.1016/j.tmaid.2022.102321 2022-04-10T00:36:42Z BACKGROUND: We aimed to elucidate which vaccines were accepted by European countries as valid proof of vaccination against COVID-19 for international travelers. METHOD: On 27-September-2021 a cross-sectional study was conducted on VisaGuide.World, that reports on valid vaccines for international travelers. Other databases, lay press and regulatory agencies were also checked. The main outcome measure was which of the vaccines included on the WHO emergency use listing (EUL) [ChAdOx1 (Vaxzevria, Covishield),BNT162b2,mRNA-1273,Ad26.CoV2.S,BBIBP-CorV,CoronaVac] and Sputnik V, were accepted in each country. The influence of the vaccines approved for COVID-19 vaccination programs on the vaccines recognized as proof of vaccination was assessed. RESULTS: There was a remarkable heterogeneity on the vaccines accepted as proof of vaccination among 46 countries. Russia accepted only one. Cyprus, Greece and Slovenia accepted all vaccines considered. Eleven countries accepted the seven WHO EUL vaccines: eight EU countries, plus Iceland, Norway and Switzerland. Seven EU countries accepted only the four EMA-authorized vaccines. Considering Covishield as equivalent to Vaxzevria, 69% of countries recognized only vaccinated travelers who received any of the vaccines approved for vaccination programs in the country of arrival as valid. CONCLUSION: Vaccines accepted as proof of vaccination should be harmonized. Accepting any of the WHO EUL vaccines would be a scientifically sound objective. Text Iceland PubMed Central (PMC) Norway Sputnik ENVELOPE(66.167,66.167,-70.833,-70.833) Travel Medicine and Infectious Disease 48 102321
institution Open Polar
collection PubMed Central (PMC)
op_collection_id ftpubmed
language English
topic Article
spellingShingle Article
Dal-Ré, Rafael
Banzi, Rita
Becker, Sören L.
Launay, Odile
Pavli, Androula
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
topic_facet Article
description BACKGROUND: We aimed to elucidate which vaccines were accepted by European countries as valid proof of vaccination against COVID-19 for international travelers. METHOD: On 27-September-2021 a cross-sectional study was conducted on VisaGuide.World, that reports on valid vaccines for international travelers. Other databases, lay press and regulatory agencies were also checked. The main outcome measure was which of the vaccines included on the WHO emergency use listing (EUL) [ChAdOx1 (Vaxzevria, Covishield),BNT162b2,mRNA-1273,Ad26.CoV2.S,BBIBP-CorV,CoronaVac] and Sputnik V, were accepted in each country. The influence of the vaccines approved for COVID-19 vaccination programs on the vaccines recognized as proof of vaccination was assessed. RESULTS: There was a remarkable heterogeneity on the vaccines accepted as proof of vaccination among 46 countries. Russia accepted only one. Cyprus, Greece and Slovenia accepted all vaccines considered. Eleven countries accepted the seven WHO EUL vaccines: eight EU countries, plus Iceland, Norway and Switzerland. Seven EU countries accepted only the four EMA-authorized vaccines. Considering Covishield as equivalent to Vaxzevria, 69% of countries recognized only vaccinated travelers who received any of the vaccines approved for vaccination programs in the country of arrival as valid. CONCLUSION: Vaccines accepted as proof of vaccination should be harmonized. Accepting any of the WHO EUL vaccines would be a scientifically sound objective.
format Text
author Dal-Ré, Rafael
Banzi, Rita
Becker, Sören L.
Launay, Odile
Pavli, Androula
author_facet Dal-Ré, Rafael
Banzi, Rita
Becker, Sören L.
Launay, Odile
Pavli, Androula
author_sort Dal-Ré, Rafael
title High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
title_short High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
title_full High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
title_fullStr High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
title_full_unstemmed High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
title_sort high heterogeneity on the accepted vaccines for covid-19 certificates in european countries
publisher Elsevier Ltd.
publishDate 2022
url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/
https://doi.org/10.1016/j.tmaid.2022.102321
long_lat ENVELOPE(66.167,66.167,-70.833,-70.833)
geographic Norway
Sputnik
geographic_facet Norway
Sputnik
genre Iceland
genre_facet Iceland
op_source Travel Med Infect Dis
op_relation http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/
http://dx.doi.org/10.1016/j.tmaid.2022.102321
op_rights © 2022 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
op_doi https://doi.org/10.1016/j.tmaid.2022.102321
container_title Travel Medicine and Infectious Disease
container_volume 48
container_start_page 102321
_version_ 1766041082065321984